Can Ozempic quiet the urge to binge eat? What we know so far
Drugs like Ozempic and Mounjaro are becoming increasingly popular for treating obesity and type 2 diabetes.
These medications belong to a group called GLP-1 agonists,...
Popular weight loss drug may increase vision loss risk
A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a higher...
New drug could offer hope for treating obesity without diet or exercise
Obesity is a serious global health problem that raises the risk of heart disease, diabetes, and some types of cancer. Yet, there are still...
New obesity drug may slow breast cancer growth
A new study has found that a drug used for treating obesity and type 2 diabetes may also help slow the growth of breast...
Obesity-linked cancer deaths have tripled in the U.S. over 20 years
Cancer deaths linked to obesity have tripled in the United States over the last 20 years, according to new research presented at ENDO 2025,...
Higher doses of this diabetes drug improve weight loss and blood sugar
Diabetes is a condition where there is too much sugar in the blood. Over time, this can become harder to control. Some medicines can...
New obesity drug could slow down breast cancer growth
A new study has found that an anti-obesity drug called tirzepatide, which is sold under the names Mounjaro for diabetes and Zepbound for obesity,...
Weight-loss medications may help restore testosterone in men, study finds
New research shows that popular anti-obesity medications could do more than just help men lose weight—they may also help bring testosterone levels back to...
Skipping meals twice a week may help people with diabetes and obesity
New research suggests that eating less just two days a week could be more helpful than other popular diet plans for people with obesity...
Obesity care: why “eat less, move more” advice is failing
For years, people living with obesity have been given the same basic advice: eat less, move more.
But while this mantra may sound simple, it’s...